
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
The short slide show summarizes 9 pearls on preventive cardiology from the landmark ACC/AHA 2019 guideline on primary CVD prevention.
Atherosclerotic cardiovascular disease (ASCVD) outcomes have improved substantially in recent years, but ASCVD remains the leading cause of morbidity and mortality worldwide.
The 2019 landmark clinical practice guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) provide
For a concise summary of key points, scroll through the slides below.






